Literature DB >> 12963604

Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.

Kirk R Wilhelmus1, Robert L Abshire, Barry A Schlech.   

Abstract

OBJECTIVE: To estimate how a corneal isolate's minimal inhibitory concentration for a fluoroquinolone agent affects the rate of clinical response of bacterial keratitis to fluoroquinolone therapy.
DESIGN: Prospective cohort study.
METHODS: Six hundred sixty-three individuals with suspected bacterial keratitis underwent diagnostic corneal scraping and were treated with topical 0.3% ciprofloxacin solution or ointment. Of 407 patients with culture-confirmed bacterial keratitis, improvement and cure rates with ciprofloxacin monotherapy were estimated for 391 who had in vitro ciprofloxacin susceptibility of the principal corneal isolate. MAIN OUTCOME MEASURES: Slitlamp biomicroscopic assessment for clinical improvement of corneal inflammation and for clinical cure with complete reepithelialization.
RESULTS: Adjusted rates of improvement and of cure were reduced, respectively, by 43% (95% confidence limits, 8%, 64%) and by 29% (95% confidence limits, 0%, 49%) among corneal infections having a ciprofloxacin minimal inhibitory concentration above 1.0 micro g/mL compared with those with more sensitive isolates.
CONCLUSIONS: Corneal infection by relatively ciprofloxacin-resistant bacteria responds more slowly to ciprofloxacin therapy. Antibacterial susceptibility testing of corneal cultures may predict the fluoroquinolone therapeutic response rate of bacterial keratitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963604     DOI: 10.1001/archopht.121.9.1229

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  26 in total

1.  Orlans HO, Hornby SJ, Bowler IC (2011) In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. Eye Jan 21 [Epub ahead of print] PMID 21252952.

Authors:  Stephen Kaye; Rose Gilbert; Henri Sueke; Timothy Neal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

2.  In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review.

Authors:  H O Orlans; S J Hornby; I C J W Bowler
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

3.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Authors:  Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2012-03-23       Impact factor: 9.079

4.  Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.

Authors:  Robert E Fintelmann; Eliza N Hoskins; Thomas M Lietman; Jeremy D Keenan; Bruce D Gaynor; Vicky Cevallos; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-04

5.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.

Authors:  Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Palanisamy Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Natalie Nardone; Kathryn J Ray; David V Glidden; Nisha R Acharya; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-28       Impact factor: 4.799

7.  Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Authors:  Aiyin Chen; Lalitha Prajna; Muthiah Srinivasan; Rajendran Mahalakshmi; John P Whitcher; Stephen McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2008-01-22       Impact factor: 5.258

8.  Prevalence and spectrum of bacterial co-infection during fungal keratitis.

Authors:  J C Pate; D B Jones; K R Wilhelmus
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

9.  Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.

Authors:  Saichi Hoshi; Ken Kikuchi; Takashi Sasaki; Chie Sotozono; Shigeru Kinoshita; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-05-19       Impact factor: 5.191

10.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.